TY - JOUR
T1 - HEPATIC ENCEPHALOPATHY AND THE γ-AMINOBUTYRIC-ACID NEUROTRANSMITTER SYSTEM
AU - Schafer, DanielF
AU - Anthony Jones, E.
PY - 1982/1/2
Y1 - 1982/1/2
N2 - γ-Aminobutyric acid (GABA), the principal inhibitory neurotransmitter of the mammalian brain, is synthesised by gut bacteria. In a rabbit model the development of hepatic encephalopathy was associated with increased levels of GABA in plasma, increased permeability of the blood-brain barrier, increased numbers of binding-sites for GABA and benzodiazepines in the brain, and a pattern of neural activity similar to that induced by drugs which activate the GABA neurotransmitter system. It is postulated that in liver failure gut-derived GABA passes through a permeable blood-brain barrier and induces its own receptors in the brain, that gut-derived GABA contributes to the neural inhibition of hepatic encephalopathy, and that an increased number of drugbinding sites mediates enhanced sensitivity to barbiturates and benzodiazepines in liver failure.
AB - γ-Aminobutyric acid (GABA), the principal inhibitory neurotransmitter of the mammalian brain, is synthesised by gut bacteria. In a rabbit model the development of hepatic encephalopathy was associated with increased levels of GABA in plasma, increased permeability of the blood-brain barrier, increased numbers of binding-sites for GABA and benzodiazepines in the brain, and a pattern of neural activity similar to that induced by drugs which activate the GABA neurotransmitter system. It is postulated that in liver failure gut-derived GABA passes through a permeable blood-brain barrier and induces its own receptors in the brain, that gut-derived GABA contributes to the neural inhibition of hepatic encephalopathy, and that an increased number of drugbinding sites mediates enhanced sensitivity to barbiturates and benzodiazepines in liver failure.
UR - http://www.scopus.com/inward/record.url?scp=0020063020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020063020&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(82)92559-4
DO - 10.1016/S0140-6736(82)92559-4
M3 - Article
C2 - 6119414
AN - SCOPUS:0020063020
SN - 0140-6736
VL - 319
SP - 18
EP - 20
JO - The Lancet
JF - The Lancet
IS - 8262
ER -